Navigating Insurance Challenges for Obesity Medications: Expert Insights

Novo Nordisk's parent company, Novo Holdings, has acquired Catalent, a fill-finish company, to enhance supply capabilities for GLP-1 weight loss drugs like Ozempic and Wegovy. Meghan Fitzgerald, a healthcare policy professor, sees this move as positive due to the supply problem in meeting patient demand. However, the persistent high costs of these drugs, around $1,000 a month, pose challenges for patients and insurance providers, especially those heavily invested in Medicare Advantage. The healthcare sector is facing headwinds such as inflation, labor shortages, and provider margin pressure, with Medicare Advantage providers being particularly exposed to risk in the near term.